Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The immunoproteasome caspase-like site β1, also known as LMP2 or PSMB9, is a catalytic subunit of the immunoproteasome. It exhibits caspase-like activity, cleaving peptide bonds after acidic residues. It plays a crucial role in antigen processing and MHC class I presentation, impacting immune responses and inflammation. As a therapeutic target, selective inhibitors are being explored for autoimmune and inflammatory diseases.
Inhibition of caspase-like proteolytic activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoproteasome caspase-like site β1 (None).